Moreover, TCGA PCa patients with high NR3C1 and FOXA1 transcript levels had increased progression-free survival over PCa patients with high NR3C1 but low FOXA1 transcript levels (Supplementary Figure S16B, C). This evidence concerns the gene FOXA1 and posterior cortical atrophy.